Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies | MicrobiomeTrials← Back to trialsNCT05327023
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-05-23Est. Completion: 2028-07-03
Enrollment target: 430 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Healthy Donors
Background
-NCI-Frederick scientists performing in vitro studies involving human specimens have a need for a reliable a…
Frederick, United StatesCompleted Oct 1, 2030
Myeloma Multiple
The BELAMI trial is an open label, multicenter, phase 2 study for patients with MM who relapsed following BCMA-directed …
Amiens, FranceEst. completion Jan 1, 2028
SUSPENDED
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
Background:
Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatmen…
Bethesda, United StatesCompleted Jan 1, 2033